Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants to five new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of non-qualified stock options to purchase 49,751 shares of Intellia’s common stock, with 33% of such options vesting on September 1, 2025, and the remainder vesting monthly thereafter until fully vested on September 1, 2027; time-based restricted stock units (“RSUs”) for 44,154 shares of Intellia’s common stock, with one-third of such RSUs vesting on September 1, 2025, 2026, and 2027; performance-based RSUs for 17,064 shares (at target) of Intellia’s common stock, with vesting criteria linked directly to Intellia’s total stockholder return over a three-year period compared to the companies comprisin
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $54.00 price target on the stock.MarketBeat
- Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingGlobeNewswire
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
NTLA
Earnings
- 8/8/24 - Miss
NTLA
Sec Filings
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- 7/24/24 - Form 4
- NTLA's page on the SEC website